The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).
Jeffrey Matous
Consultant or Advisory Role - Celgene
Honoraria - Celgene
David Samuel DiCapua Siegel
Honoraria - Celgene; Merck; Millennium; Onyx
Hien Kim Duong
Honoraria - Celgene
Research Funding - Celgene
Claudia Kasserra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Lars Sternas
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Christian Jacques
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth Klesczewski
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Mohamed H. Zaki
Research Funding - Celgene
Jatin J. Shah
Consultant or Advisory Role - Array BioPharma; Celgene; Novartis; Onyx
Research Funding - Array BioPharma; Bristol-Myers Squibb; Celgene; Millennium; Novartis; Onyx